| scholarly article | Q13442814 |
| P356 | DOI | 10.1002/1097-0142(20000815)89:4<783::AID-CNCR10>3.0.CO;2-Q |
| P698 | PubMed publication ID | 10951341 |
| P50 | author | John H. Healey | Q6236872 |
| Paul Meyers | Q37828974 | ||
| Enrique de Alava | Q60674757 | ||
| Denis Heng Yan Leung | Q67877769 | ||
| P2093 | author name string | Antonescu CR | |
| Pardo-Mindán FJ | |||
| Huvos AG | |||
| Ladanyi M | |||
| Panizo A | |||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 783-792 | |
| P577 | publication date | 2000-08-01 | |
| P1433 | published in | Cancer | Q326041 |
| P1476 | title | Prognostic impact of P53 status in Ewing sarcoma | |
| P478 | volume | 89 |
| Q37185811 | A rare case of extraskeletal Ewing's sarcoma/primitive neuroectodermal tumor developing in maxillary sinus of an old patient |
| Q40458621 | Adenovirus-mediated p53 gene therapy in pediatric soft-tissue sarcoma cell lines: sensitization to cisplatin and doxorubicin. |
| Q33272380 | Alterations of G1-S checkpoint in chordoma: the prognostic impact of p53 overexpression |
| Q21198840 | An integrated analysis of miRNA and gene copy numbers in xenografts of Ewing's sarcoma |
| Q77697202 | Apoptosis and expression of its regulatory proteins in soft tissue sarcomas |
| Q80510573 | Biology and therapy of malignant solid tumors in childhood |
| Q36907188 | Biomarkers in Ewing Sarcoma: The Promise and Challenge of Personalized Medicine. A Report from the Children's Oncology Group. |
| Q34260723 | Cell Cycle Deregulation in Ewing's Sarcoma Pathogenesis |
| Q28535586 | Characterization and drug resistance patterns of Ewing's sarcoma family tumor cell lines |
| Q27027664 | Children's Oncology Group's 2013 blueprint for research: bone tumors |
| Q36145215 | Clinical features of molecular pathology of solid tumours in childhood |
| Q38167715 | Clinicopathological and molecular spectrum of ewing sarcomas/PNETs, including validation of EWSR1 rearrangement by conventional and array FISH technique in certain cases |
| Q34700651 | Copy Number Alterations and Methylation in Ewing's Sarcoma |
| Q33813608 | Current treatment protocols have eliminated the prognostic advantage of type 1 fusions in Ewing sarcoma: a report from the Children's Oncology Group |
| Q37135628 | EWS-FLI1 suppresses NOTCH-activated p53 in Ewing's sarcoma |
| Q34575191 | Ewing sarcoma of the bone in children under 6 years of age |
| Q53561818 | Ewing's sarcoma metastasis to the gastric wall in a 72-year-old patient. |
| Q35057457 | Ewing's sarcoma: diagnostic, prognostic, and therapeutic implications of molecular abnormalities |
| Q39113281 | Factors Affecting EWS-FLI1 Activity in Ewing's Sarcoma |
| Q52629172 | IRE1α-XBP1 inhibitors exerted anti-tumor activities in Ewing's sarcoma |
| Q28244685 | In Ewing's sarcoma CCN3(NOV) inhibits proliferation while promoting migration and invasion of the same cell type |
| Q35210018 | Mechanisms of sarcoma development |
| Q80387809 | Microsatellite instability in Ewing tumor is not associated with loss of mismatch repair protein expression |
| Q74020557 | Molecular analysis of the 9p21 locus and p53 genes in Ewing family tumors |
| Q37180948 | Molecular approaches to sarcoma therapy |
| Q39793825 | Molecular characterization of commonly used cell lines for bone tumor research: a trans-European EuroBoNet effort |
| Q35183100 | Molecular genetics of pediatric soft tissue tumors: clinical application |
| Q36308536 | P53 immunohistochemical scoring: an independent prognostic marker for patients after hepatocellular carcinoma resection |
| Q39823354 | Pathobiologic Markers of the Ewing Sarcoma Family of Tumors: State of the Art and Prediction of Behaviour |
| Q41847093 | Pathology of Ewing's sarcoma/PNET: Current opinion and emerging concepts |
| Q88304388 | Plasma DNA-based molecular diagnosis, prognostication, and monitoring of patients with EWSR1 fusion-positive sarcomas |
| Q52852427 | Ploidy and karyotype complexity are powerful prognostic indicators in the Ewing's sarcoma family of tumors: a study by the United Kingdom Cancer Cytogenetics and the Children's Cancer and Leukaemia Group |
| Q34050631 | Primary intracranial Ewing sarcoma with an unusually aggressive course: A case report and review of the literature |
| Q53554365 | Primitive neuroectodermal tumor arising in the colon: report of a case |
| Q47629124 | Primitive neuroectodermal tumor of the kidney |
| Q36644524 | Prognostic impact of chromosomal aberrations in Ewing tumours |
| Q36895474 | Prognostic significance of p16 INK4a alteration for Ewing sarcoma: a meta-analysis |
| Q46477265 | Prognostic significance of p53 expression in malignant bone tumors: a meta-analysis |
| Q34226841 | Quantification of the heterogeneity of prognostic cellular biomarkers in ewing sarcoma using automated image and random survival forest analysis |
| Q36562720 | Recent advances in the molecular pathogenesis of Ewing's sarcoma |
| Q35810123 | Recent progress in predictive biomarkers for metastatic recurrence of human hepatocellular carcinoma: a review of the literature |
| Q36363792 | Regulation of apoptosis and proliferation in Ewing's sarcoma--opportunities for targeted therapy |
| Q40645830 | Response of Ewing tumor cells to forced and activated p53 expression |
| Q36010989 | Reticulon Protein-1C: A New Hope in the Treatment of Different Neuronal Diseases |
| Q26801785 | Sequencing Overview of Ewing Sarcoma: A Journey across Genomic, Epigenomic and Transcriptomic Landscapes |
| Q37236770 | Systems biology of Ewing sarcoma: a network model of EWS-FLI1 effect on proliferation and apoptosis |
| Q41303735 | Targeting the p53 Pathway in Ewing Sarcoma. |
| Q38360556 | The Id2 gene is a novel target of transcriptional activation by EWS-ETS fusion proteins in Ewing family tumors. |
| Q35957979 | The clinical use of biomarkers as prognostic factors in Ewing sarcoma |
| Q34668320 | The prognostic molecular markers in hepatocellular carcinoma |
| Q35224434 | Tumoral TP53 and/or CDKN2A alterations are not reliable prognostic biomarkers in patients with localized Ewing sarcoma: a report from the Children's Oncology Group |
| Q26782649 | Twenty Years on: What Do We Really Know about Ewing Sarcoma and What Is the Path Forward? |
| Q26829949 | Understanding the Biology of Bone Sarcoma from Early Initiating Events through Late Events in Metastasis and Disease Progression |
| Q37323049 | Variability in functional p53 reactivation by PRIMA-1(Met)/APR-246 in Ewing sarcoma. |
| Q40834415 | Variability in gene expression patterns of Ewing tumor cell lines differing in EWS-FLI1 fusion type |
Search more.